| For: | Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol 2014; 20(24): 7675-7685 [PMID: 24976705 DOI: 10.3748/wjg.v20.i24.7675] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i24/7675.htm |
| Number | Citing Articles |
| 1 |
Xiao-Jun Lin, Xiang-Ming Lao, Ming Shi, Sheng-Ping Li. Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment. Digestive Diseases and Sciences 2016; 61(9) doi: 10.1007/s10620-016-4167-5
|
| 2 |
Su-Su Zhang, Jin-Xia Liu, Jing Zhu, Ming-Bing Xiao, Cui-Hua Lu, Run-Zhou Ni, Li-Shuai Qu. Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis. Japanese Journal of Clinical Oncology 2019; 49(7) doi: 10.1093/jjco/hyz046
|
| 3 |
Jiaming Shen, Xia Wang, Guangde Yang, Li Li, Juanjuan Fu, Wei Xu, Qingqiao Zhang, Xiucheng Pan. Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors. Journal of Hepatocellular Carcinoma 2024; doi: 10.2147/JHC.S431191
|
| 4 |
Jung Il Lee. Reactivation of Hepatitis B Virus in Patients with Rheumatologic Disease Treated with Biologic Disease Modifying Anti-rheumatic Drugs: Screening and Treatment. Journal of Rheumatic Diseases 2015; 22(5) doi: 10.4078/jrd.2015.22.5.282
|
| 5 |
Shaowei Xu, Qingqing Pang, Meng Wei, Danxi Liu, Du Yuan, Tao Bai, Xiaobo Wang, Zhihong Tang, Feixiang Wu. Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors. Frontiers in Cellular and Infection Microbiology 2025; 15 doi: 10.3389/fcimb.2025.1598193
|
| 6 |
Pei-Chang Lee, Yee Chao, Ming-Huang Chen, Keng-Hsin Lan, I-Cheng Lee, Ming-Chih Hou, Yi-Hsiang Huang. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer 2020; 8(2) doi: 10.1136/jitc-2020-001072
|
| 7 |
Venessa Pattullo. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World Journal of Hepatology 2015; 7(7): 954-967 doi: 10.4254/wjh.v7.i7.954
|
| 8 |
Chanana D. Tsayang, Emily Schanzer, Bonolo B. Phinius, Graceful Mulenga, Kesaobaka Molebatsi, Kwana Lechiile, Lynnette Bhebhe, Tsholofelo Ratsoma, Gorata G. A. Mpebe, Fredah Mulenga, Basetsana K. S. Phakedi, Wonderful T. Choga, Madisa Mine, Shahin Lockman, Joseph N. Jarvis, Sikhulile Moyo, Motswedi Anderson, Simani Gaseitsiwe. High Prevalence of Hepatitis B Virus Infection Among People Living with Advanced HIV Disease in Botswana. Biomedicines 2026; 14(6) doi: 10.3390/biomedicines14061229
|
| 9 |
Melisa Dirchwolf, Fernando Bessone. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World Journal of Hepatology 2016; 8(8): 385-394 doi: 10.4254/wjh.v8.i8.385
|
| 10 |
Jiang-feng Xu, Xi-yu Liu, Shuai Wang, Huai-xi Wen. Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus: a novel classification. World Journal of Surgical Oncology 2015; 13(1) doi: 10.1186/s12957-015-0493-x
|
| 11 |
Yiqi Yu, Jingwen Ai, Wenhong Zhang. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2017; 11(10) doi: 10.1080/17474124.2017.1343665
|
| 12 |
Harjot K. Bedi, Daljeet Chahal, Christopher F. Lowe, Gordon Ritchie, Trana Hussaini, Vladimir Marquez, Eric M. Yoshida. Occult Hepatitis B Reactivation after Liver Transplant: The Role of a Novel Mutation in the Surface Antigen. Journal of Clinical and Translational Hepatology 2020; 0(000) doi: 10.14218/JCTH.2020.00090
|
| 13 |
Chih-An Shih, Wen-Chi Chen. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World Journal of Clinical Cases 2021; 9(21): 5769-5781 doi: 10.12998/wjcc.v9.i21.5769
|
| 14 |
Chenlu Liu, Le Chang, Ying Yan, Huimin Ji, Jie Ma, Huizhen Sun, Lunan Wang. Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors. Current Treatment Options in Oncology 2026; 27(1) doi: 10.1007/s11864-026-01395-z
|
| 15 |
Tae‐Se Kim, Dong Hyun Sinn, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik. Hepatitis B virus DNA levels and overall survival in hepatitis B‐related hepatocellular carcinoma patients with low‐level viremia. Journal of Gastroenterology and Hepatology 2019; 34(11) doi: 10.1111/jgh.14750
|
| 16 |
Zhi-Wei Jian, Xi-Wen Wu, Zhen-Xin Chen, Jun-Cheng Wang, Jing-Yuan Peng, Xiang-Ming Lao. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. Digestive Diseases and Sciences 2019; 64(8) doi: 10.1007/s10620-019-05543-4
|
| 17 |
Zhenyun Yang, Renguo Guan, Yizhen Fu, Dandan Hu, Zhongguo Zhou, Minshan Chen, Yaojun Zhang. Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors. Frontiers in Cellular and Infection Microbiology 2024; 14 doi: 10.3389/fcimb.2024.1336619
|
| 18 |
Bi Sheng, Dong Wang, Jingjing Wang. Hepatitis B Virus Reactivation in Patients With HBV-Related Advanced Hepatocellular Carcinoma Undergoing Lenvatinib and Camrelizumab Treatment. Cancer Control 2025; 32 doi: 10.1177/10732748241309046
|
| 19 |
Eileen L. Yoon. Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients. The Korean Journal of Gastroenterology 2019; 74(5) doi: 10.4166/kjg.2019.74.5.258
|
| 20 |
Tianyu Ma, Feilong Zhao, Linmei Yao, Chuanchun Mao, Yuan Tian, Youyou Ma, Fanyun Kong, Ruyu Liu. The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma. Clinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01928-0
|
| 21 |
Jiaming Shen, Xia Wang, Ningning Wang, Shifei Wen, Guangde Yang, Li Li, Juanjuan Fu, Xiucheng Pan. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors. Frontiers in Cellular and Infection Microbiology 2023; 13 doi: 10.3389/fcimb.2023.1179689
|
| 22 |
KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and Molecular Hepatology 2019; 25(2) doi: 10.3350/cmh.2019.1002
|
| 23 |
Thomas M. Ruli, Ethan D. Pollack, Atul Lodh, Charles D. Evers, Christopher A. Price, Mohamed Shoreibah. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review. Cancers 2024; 16(11) doi: 10.3390/cancers16112042
|
| 24 |
Jeong Won Jang, Sun Hong Yoo, Hee Chul Nam, Bo Hyun Jang, Pil Soo Sung, Sung, Won Lee, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Seung Kew Yoon, Jong Young Choi. Association of Prophylactic Anti–Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy. Clinical Infectious Diseases 2020; 71(3) doi: 10.1093/cid/ciz860
|
| 25 |
Min-Ke He, Chuan Peng, Yang Zhao, Run-Bin Liang, Zhi-Cheng Lai, Anna Kan, Qi-Jiong Li, Wei Wei, Yao-Jun Zhang, Min-Shan Chen, Rong-Ping Guo, Ming Shi. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunology, Immunotherapy 2021; 70(11) doi: 10.1007/s00262-021-02911-w
|
| 26 |
Zhonghu Li, Xin Zhao, Peng Jiang, Senlin Xiao, Guo Wu, Kai Chen, Xi Zhang, Hui Liu, Xiuguo Han, Shuguang Wang, Xiaowu Li. HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma. Medicine 2016; 95(31) doi: 10.1097/MD.0000000000004224
|
| 27 |
Margarita Papatheodoridi, Maria Tampaki, Anna S. Lok, George V. Papatheodoridis. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology 2022; 75(5) doi: 10.1002/hep.32241
|
| 28 |
Zefeng Du, Zhicheng Lai, Yexing Huang, Hailong Chen, Ping Ma, Qijiong Li, Wei Wei, Yaojun Zhang, Minshan Chen, Binkui Li, Li Xu, Ming Shi, Anna Kan, Minke He. HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study. Clinical Cancer Research 2026; 32(4) doi: 10.1158/1078-0432.CCR-25-2859
|
| 29 |
Yurou Jin, Chao Jin, Ronghui Xie, Jingming Zhang, Guangmin Wei, Ling Zheng. HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1765054
|
| 30 |
Venessa Pattullo. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clinical and Molecular Hepatology 2016; 22(2) doi: 10.3350/cmh.2016.0024
|
| 31 |
KASL clinical practice guidelines: management of chronic hepatitis B. Clinical and Molecular Hepatology 2016; 22(1) doi: 10.3350/cmh.2016.22.1.18
|
| 32 |
Jonggi Choi, Young-Suk Lim. Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy. The Journal of Infectious Diseases 2017; 216(suppl_8) doi: 10.1093/infdis/jix178
|
| 33 |
Jeong Won Jang, Young Woon Kim, Sung Won Lee, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Kyu Won Chung, Isabelle A Chemin. Reactivation of Hepatitis B Virus in HBsAg-Negative Patients with Hepatocellular Carcinoma. PLOS ONE 2015; 10(4) doi: 10.1371/journal.pone.0122041
|
| 34 |
Soheil Tavakolpour, Seyed Moayed Alavian, Shahnaz Sali. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review. Hepatitis Monthly 2016; 16(4) doi: 10.5812/hepatmon.35810
|
| 35 |
Diego A S Toesca, Bulat Ibragimov, Amanda J Koong, Lei Xing, Albert C Koong, Daniel T Chang. Strategies for prediction and mitigation of radiation-induced liver toxicity. Journal of Radiation Research 2018; 59(suppl_1) doi: 10.1093/jrr/rrx104
|
| 36 |
Joe Sasadeusz, Andrew Grigg, Peter D. Hughes, Seng Lee Lim, Michaela Lucas, Geoff McColl, Sue Anne McLachlan, Marion G. Peters, Nicholas Shackel, Monica Slavin, Vijaya Sundararajan, Alexander Thompson, Joseph Doyle, James Rickard, Peter De Cruz, Robert G. Gish, Kumar Visvanathan. Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease 2019; 23(3) doi: 10.1016/j.cld.2019.04.011
|
| 37 |
Shike Lou, Zhujun Cao, Wanqing Chi, Xiaoyin Wang, Mingyang Feng, Lanyi Lin, Yezhou Ding, Kehui Liu, Lihong Qu, Gangde Zhao, Shisan Bao, Hui Wang. The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1164309
|
| 38 |
KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and Molecular Hepatology 2022; 28(2) doi: 10.3350/cmh.2022.0084
|
| 39 |
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip. Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer. Alimentary Pharmacology & Therapeutics 2026; 63(3) doi: 10.1111/apt.70367
|
| 40 |
Shousheng Liu, Jinfa Lai, Ning Lyu, Qiankun Xie, Huijiao Cao, Dabiao Chen, Meng He, Bei Zhang, Ming Zhao. Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy. Frontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.582504
|
| 41 |
Xiaoguang Wang, Xiaodan Yang, Fei Chen, Shaohan Wu, Zhengwei Song, Jianguo Fei, Giovanni Marasco. Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research. Canadian Journal of Gastroenterology and Hepatology 2021; 2021(1) doi: 10.1155/2021/8864655
|
| 42 |
Dong Hyun Sinn, Danbee Kang, Yun Soo Hong, Kwang Cheol Koh, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak, Luca Rinaldi. Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. PLOS ONE 2021; 16(8) doi: 10.1371/journal.pone.0255624
|
| 43 |
Jong-In Chang, Dong Hyun Sinn, Hyun Cho, Seonwoo Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik. Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. Digestive Diseases and Sciences 2022; 67(9) doi: 10.1007/s10620-021-07312-8
|
| 44 |
Zhikai Zheng, Jiongliang Wang, Tianqing Wu, Minrui He, Juncheng Wang, Yangxun Pan, Jinbin Chen, Dandan Hu, Li Xu, Yaojun Zhang, Minshan Chen, Zhongguo Zhou. Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy. Journal of Hepatocellular Carcinoma 2023; doi: 10.2147/JHC.S436062
|